Endothelial dysfunction over the course of coronary artery disease

European Heart Journal

Volumn 34, Issue 41, 2013, Pages

  Gutiérrez, Enrique ^a   Flammer, Andreas J ^b   Lerman, Lilach O ^c   Elízaga, Jaime ^a   Lerman, Amir ^c   Francisco, Fernández Avilés ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MAYO CLINIC   (United States)

Author keywords

Acetylcholine; Coronary heart disease; Endothelial dysfunction; Heart failure; Heart transplant

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; BRADYKININ; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EVEROLIMUS; MUSCARINIC RECEPTOR; NITRIC OXIDE; PACLITAXEL; PROSTACYCLIN; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SEROTONIN; SEROTONIN RECEPTOR; THROMBOXANE A2; THROMBOXANE RECEPTOR; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTIPROLIFERATIVE ACTIVITY; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; BARE METAL STENT; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN-STENT RESTENOSIS; INFLAMMATION; INTRAVASCULAR ULTRASOUND; LEUKOCYTE ADHERENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SHEAR STRESS; SMOOTH MUSCLE RELAXATION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; TONOMETRY; VASCULAR SMOOTH MUSCLE;

ACETYLCHOLINE; CORONARY HEART DISEASE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART TRANSPLANT;

ACUTE CORONARY SYNDROME; BLOOD CIRCULATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MANOMETRY; MICROVESSELS; STENTS; ULTRASONOGRAPHY, INTERVENTIONAL; VASODILATION;

EID: 84890104994     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht351     Document Type: Review

References (101)

1. de Agostini AI,Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990;111:1293-1304.
2. van Hinsbergh WM. Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation. Arterioscler Thromb Vasc Biol 1997;17: 1018-1023.
3. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 2004;95:343-353.
4. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
5. Griendling KK, Harrison DG, AlexanderRW. Biology of the vessel wall. In: Fuster V, Walsh R, Harrington R, (eds). Hurst's The Heart. 13th ed. Mcgraw-hill; 2010.
6. Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease Eur Heart J 2010;31:2741-2748.
7. Luscher TF, Flammer AJ, Lerman A. Assessment of coronary vasoreactivity and the microcirculation. In: Eeckhout E SP, Wijns W, Vahanian A, van Sambeek M, De Palma R, (eds). Percutaneous Interventional Cardiovascular Medicine: The PCR-EAPCI Textbook. Toulouse, France: Europa Edition; 2012.
8. Lerman A, Holmes DR, Herrmann J, Gersh BJ. Microcirculatory dysfunction in ST-elevation myocardial infarction: Cause, consequence, or both Eur Heart J 2007;28:788-797.
9. Britten MB, Zeiher AM, Schachinger V. Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome. Coron Artery Dis 2004;15:259-264.
10. Albertal M, Voskuil M, Piek JJ, de Bruyne B, Van Langenhove G, Kay PI, Costa MA, Boersma E, Beijsterveldt T, Sousa JE, Belardi JA, Serruys PW. Coronary flow velocity reserve after percutaneous interventions is predictive of periprocedural outcome. Circulation 2002;105:1573-1578.
11. Herrmann J, Haude M, Lerman A, Schulz R, Volbracht L, Ge J, Schmermund A, Wieneke H, von Birgelen C, Eggebrecht H, Baumgart D, Heusch G, Erbel R. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation 2001;103:2339-2345.
12. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005; 26:667-674.
13. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: From research into clinical practice. Circulation 2012;126:753-767.
14. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, Cosentino F, Deanfield J, Gallino A, Ikonomidis I, Kremastinos D, Landmesser U, Protogerou A, Stefanadis C, Tousoulis D, Vassalli G, Vink H, Werner N, Wilkinson I, Vlachopoulos C. Methods for evaluating endothelial function: A position statement from the European Society of CardiologyWorking Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011;18:775-789.
15. Ludmer PL, Selwyn AP, Shook TL,Wayne RR, Mudge GH, AlexanderRW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051.
16. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989;80:458-465.
17. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Longterm follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954.
18. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
19. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrage D, Lieberman EH, Ganz P, Creager MA, YeungAC, Selwyn AP. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995;26:1235-1241.
20. Kuvin JT, Patel AR, Sliney KA, PandianNG, Sheffy J, Schnall RP, Karas RH, Udelson JE. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003;146:168-174.
21. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004;44:2137-2141.
22. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol 2006;101:545-548.
23. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:e584-e636.
24. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497.
25. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunctionmayoccur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994;23:833-843.
26. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-175.
27. Panza JA, Quyyumi AA, Brush JJ, Epstein SE. Abnormal endothelium- dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
28. Makimattila S, Virkamaki A, Groop PH, Cockcroft J, Utriainen T, Fagerudd J, Yki-Jarvinen H. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 1996;94:1276-1282.
29. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993;88:2541-2547.
30. Yasue H, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early coronary atherosclerosis. Circulation 1990;81:482-490.
31. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. The ageing endothelium, cardiovascular risk and disease in man. Exp Physiol 2009;94:317-321.
32. Lerman A, Cannan CR, Higano SH, Nishimura RA, Holmes DR Jr. Coronary vascular remodeling in association with endothelial dysfunction. Am J Cardiol 1998;81: 1105-1109.
33. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation 2005;111: 363-368.
34. Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 1997;96:3390-3395.
35. Reriani MK, Lerman LO, Lerman A. Endothelial function as a functional expression of cardiovascular risk factors. Biomark Med 2010;4:351-360.
36. Li J, Flammer AJ, Nelson RE, Gulati R, Friedman PA, Thomas RJ, Sandhu NP, Reriani MK, Lerman LO, Lerman A. Normal vascular function as a prerequisite for the absence of coronary calcification in patients free of cardiovascular disease and diabetes. Circ J 2012;76:2705-2710.
37. Papaioannou GI, Kasapis C, Seip RL, Grey NJ, Katten D,Wackers FJ, Inzucchi SE, Engel S, Taylor A, Young LH, Chyun DA, Davey JA, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller GV. Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. J Nucl Cardiol 2006;13: 362-368.
38. Li J, Flammer AJ, Lennon RJ, Nelson RE, Gulati R, Friedman PA, Thomas RJ, Sandhu NP, Hua Q, Lerman LO, Lerman A. Comparison of the effect of the metabolic syndrome and multiple traditional cardiovascular risk factors on vascular function. Mayo Clin Proc 2012;87:968-975.
39. Suzuki T, Hirata K, Elkind MS, Jin Z, Rundek T, Miyake Y, Boden-Albala B, Di Tullio MR, Sacco R, Homma S. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: The Northern Manhattan Study (NOMAS). Am Heart J 2008;156:405-410.
40. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation 2007;115:2390-2397.
41. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, PostW, Lima JA, Crouse JR, HerringtonDM.Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: The multi-ethnic study of atherosclerosis. Circulation 2009;120:502-509.
42. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol 2008;51: 997-1002.
43. Anderson TJ, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H, Hildebrand K, Fung M, Verma S, Lonn EM. Microvascular function predicts cardiovascular events in primary prevention: Long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation 2011;123:163-169.
44. Lind L, Berglund L, Larsson A, Sundstrom J. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation 2011;123: 1545-1551.
45. Kern MJ, Lerman A, Bech JW, De Bruyne B, Eeckhout E, Fearon WF, Higano ST, Lim MJ, Meuwissen M, Piek JJ, Pijls NH, Siebes M, Spaan JA. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: A scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. Circulation 2006;114:1321-1341.
46. Zeiher AM, Krause T, Schachinger V, Minners J, Moser E. Impaired endotheliumdependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995;91:2345-2352.
47. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
48. Nitenberg A, Ledoux S, Valensi P, Sachs R, Attali JR, Antony I. Impairment of coronary microvascular dilation in response to cold pressor - induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes 2001;50:1180-1185.
49. Nitenberg A, Valensi P, Sachs R, Cosson E, Attali JR, Antony I. Prognostic value of epicardial coronary artery constriction to the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care 2004;27:208-215.
50. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010;31:1142-1148.
51. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658.
52. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-2678.
53. Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol 2004; 94:294-299.
54. Lavi S, Bae JH, Rihal CS, Prasad A, Barsness GW, Lennon RJ, Holmes DR Jr, Lerman A. Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart 2009;95: 1525-1530.
55. Hamasaki S, Tei C. Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. J Cardiol 2011;57:231-238.
56. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-236.
57. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 2007;71: 220-225.
58. Kim JW, Suh SY, Choi CU, Na JO, Kim EJ, Rha SW, Park CG, Seo HS, Oh DJ. Sixmonth comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent vs. Paclitaxel-eluting stent. JACC Cardiovasc Interv 2008;1: 65-71.
59. KimJW, Seo HS, Park JH,NaJO, Choi CU, Lim HE, Kim EJ, RhaSW, ParkCG,OhDJ. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus-vs. a sirolimus-eluting stent: Differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009;53:1653-1659.
60. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
61. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, SerruysPW. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: Indirect finding of vascular reparative therapy Eur Heart J 2012; 33:1325-1333.
62. Lim SH, Flammer AJ, Yoon MH, Lennon RJ, Gulati R, Mathew V, Rihal CS, Lerman LO, Lerman A. The long-term effect of coronary stenting on epicardial and microvascular endothelial function. Circ Cardiovasc Interv 2012;5:523-529.
63. Patti G, Pasceri V, Melfi R, Goffredo C, Chello M, D'Ambrosio A, Montesanti R, Di Sciascio G. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 2005;111:70-75.
64. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006;92:441-444.
65. Elbaz M, Carrie D, Baudeux JL, Arnal JF, Maupas E, Lotterie JA, Perret B, Puel J. High frequency of endothelial vasomotor dysfunction after acute coronary syndromes in non-culprit and angiographically normal coronary arteries: A reversible phenomenon. Atherosclerosis 2005;181:311-319.
66. Fichtlscherer S, Rosenberger G,Walter G, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-1006.
67. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: Further evidence for the existence of the 'vulnerable' patient. Circulation 2004;110:1926-1932.
68. Careri G, Nerla R, Di Monaco A, Russo G, Stazi A, Villano A, Sestito A, Lanza GA, Crea F. Clinical correlates and prognostic value offlowmediated dilation in patients with non-ST segment elevation acute coronary syndromes. Am J Cardiol 2013;111: 51-57.
69. Bissinger A, Grycewicz T, GrabowiczW, Lubinski A. Endothelial function and left ventricular remodeling in diabetic and non-diabetic patients after acute coronary syndrome. Med Sci Monit 2011;17:CR73-CR77.
70. Michel T.NOway to relax: The complexities of coupling nitric oxide synthase pathways in the heart. Circulation 2010;121:484-486.
71. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dikalov S, Harrison DG, Dudley SC Jr. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 2010;121:519-528.
72. Ma LN, Zhao SP, Gao M, Zhou QC, Fan P. Endothelial dysfunction associated with left ventricular diastolic dysfunction in patients with coronary heart disease. Int J Cardiol 2000;72:275-279.
73. Shechter M, Matetzky S, Arad M, Feinberg MS, Freimark D. Vascular endothelial function predicts mortality risk in patients with advanced ischaemic chronic heart failure†. Eur J Heart Fail 2009;11:588-593.
74. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, Drexler H. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005;26:65-69.
75. de Berrazueta JR, Guerra-Ruiz A, Garća-UnzuetaMT, Mart́n Toca G, Sainz Laso R, Sáez de Adana M, Casanova Mart́n MA, Cobo M, Llorca J. Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. Eur J Heart Fail 2010;12: 477-483.
76. Damy T, Ratajczak P, Shah AM, Camors E, Marty I, Hasenfuss G, Marotte F, Samuel JL, Heymes C. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004;363:1365-1367.
77. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 2012;60:1455-1469.
78. Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald PS. Increased nitric oxide production in heart failure. Lancet 1994;344:373-374.
79. Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep 2008;60:119-126.
80. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, Sutton MG, Selwyn AP, Alexander RW. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990;81:772-779.
81. Bitar F, Lerman A, AkhterMW, Hatamizadeh P, Janmohamed M, Khan S, Elkayam U. Variable response of conductance and resistance coronary arteries to endothelial stimulation in patients with heart failure due to nonischemic dilated cardiomyopathy. J Cardiovasc Pharmacol Ther 2006;11:197-202.
82. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84: 1589-1596.
83. Klosinska M, Rudzinski T, Grzelak P, Stefanczyk L, Drozdz J, Krzeminska-Pakula M. Endothelium-dependent and-independent vasodilation is more attenuated in ischaemic than in non-ischaemic heart failure. Eur J Heart Fail 2009;11:765-770.
84. Belardinelli R, Capestro F, Misiani A, Scipione P, Georgiou D. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy. Eur J Cardiovasc Prev Rehabil 2006;13: 818-825.
85. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98:2709-2715.
86. Akar JG, Al-Chekakie MO, Fugate T, Moran L, Froloshki B, Varma N, Santucci P, Wilber DJ, Matsumura ME. Endothelial dysfunction in heart failure identifies responders to cardiac resynchronization therapy. Heart Rhythm 2008;5: 1229-1235.
87. Enomoto K, Yamabe H, Toyama K, Matsuzawa Y, Yamamuro M, Uemura T, Morihisa K, Iwashita S, Kaikita K, Sugiyama S, Ogawa H. Improvement effect on endothelial function in patients with congestive heart failure treated with cardiac resynchronization therapy. J Cardiol 2011;58:69-73.
88. Tesselaar E, Schiffer A, Widdershoven J, Broers H, Hendriks E, Luijten K, Creusen J. Effect of cardiac resynchronization therapy on endothelium-dependent vasodilatation in the cutaneous microvasculature. Pacing Clin Electrophysiol 2012;35:377-384.
89. Fish RD, Nabel EG, Selwyn AP, Ludmer PL, Mudge GH, KirshenbaumJM, Schoen FJ, Alexander RW, Ganz P. Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest 1988;81:21-31.
90. Davis SF, YeungAC, Meredith IT, Charbonneau F, Ganz P, Selwyn AP, Anderson TJ. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996;93:457-462.
91. Hollenberg SM, Klein LW, Parrillo JE, Scherer M, Burns D, Tamburro P, Oberoi M, Johnson MR, Costanzo MR. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001;104: 3091-3096.
92. Sudhir K, MacGregor JS, DeMarco T, De Groot CJ, Taylor RN, Chou TM, Yock PG, Chatterjee K. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994;90:3018-3023.
93. Edwards BS, Hunt SA, Fowler MB, Valantine HA, AndersonLM, Lerman A. Effect of cyclosporine on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol 1991;67:782-784.
94. Diederich D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994;23(6 Pt 2):957-961.
95. Raichlin E, Prasad A, Kremers WK, Edwards BS, Rihal CS, Lerman A, Kushwaha SS. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients. Eur Heart J 2009;30:1356-1363.
96. Kubo SH, Rector TS, Bank AJ, Tschumperlin LK, Raij L, Brunsvold N, Kraemer MD. Effects of cardiac transplantation onendothelium-dependent dilation of the peripheral vasculature in congestive heart failure. Am J Cardiol 1993;71:88-93.
97. Roig E, Cuppoletti A, Masotti M, Kianco R, Vallejos I, Sitges M, Ortiz J, Perez-Villa F. Assessment of peripheral endothelial-dependent vasodilatation within the first year after heart transplantation. J Heart Lung Transplant 2009;28:299-304.
98. Cuppoletti A, Sitges M, Perez Villa F, Orus J,Magrina J, Roig E. Impairment in forearm endothelium-dependent vasodilation after heart transplantation. Transplant Proc 2003;35:2011-2013.
99. Andreassen AK, Kvernebo K, Jorgensen B, Simonsen S, Kjekshus J, Gullestad L. Exercise capacity in heart transplant recipients: Relation to impaired endotheliumdependent vasodilation of the peripheral microcirculation. Am Heart J 1998;136: 320-328.
100. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008;117: 2467-2474.
101. Flammer AJ, Luscher TF.Humanendothelial dysfunction: EDRFs. Pflugers Arch 2010; 459:1005-1013.